1. Hepatitis C virus core antigen in the management of patients treated with new direct-acting antivirals.
- Author
-
Arboledas JCA, Guerrero IP, Rodríguez MJB, Martos ET, Pérez AB, León CC, Sierra Sánchez JF, Prieto MDL, Porcuna NC, Mochón MDO, Macías J, de la Iglesia Salgado A, Granger JR, Fernández MD, Lozano IG, Ramírez ER, Rivero A, Del Carmen Lozano Domínguez M, Viciana I, Montemayor JCG, and García FG
- Subjects
- Female, Humans, Male, Middle Aged, RNA, Viral blood, Retrospective Studies, Antiviral Agents therapeutic use, Drug Monitoring methods, Hepatitis C, Chronic drug therapy, Viral Core Proteins blood
- Abstract
We evaluated the utility of Architect core antigen assay® Abbott Diagnostics (HCVAg) for monitoring patients with HCV infection and compared to HCV-RNA quantification (Cobas Ampliprep TaqMan-Roche Diagnostics). Samples from 262 patients were studied. Mean baseline HCV RNA and HCVAg levels were similar for responders (6.2 log IU/mL and 3.4 log fmol/L) and non-responders (6.1 log IU/mL and 3.2 log fmol/L), respectively. Only 10 patients failed to achieve SVR12 and all were detected by both assays. To evaluate HCVAg quantification as a tool for the detection of failure to DAAs, we performed a retrospective study of 132 non-responder patients. Mean HCV RNA and HCVAg levels at the time of detection of therapeutic failure were 5.88±0.97 log IU/mL and 3.19±0.79 log fmol/L, respectively. HCVAg (>3 fmol/L) was detected in 130/132 patients (98.5%). HCVAg assay was useful for patient selection and for evaluating virological response to DAAs in the real world., (Copyright © 2017 Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF